When Federalism Becomes a Loophole: The Bengaluru Fake-Drug Bust and India's Fractured Pharma Oversight

The Bengaluru Bust Is a Regulatory Design Problem, Not Just a Crime Story It is

tempting to read the Bengaluru counterfeit drug bust as a story about criminals who got caught. The more useful reading is structural: how did a network manage to repackage expired cancer and ICU drugs and route them through a colluding pharmacy into 90-plus hospitals for months, seemingly undetected?

The answer lies in how India actually splits drug regulation between two levels of government that don't share a single, unified enforcement view of the supply chain. Under the Drugs and Cosmetics Act, 1940, manufacturing licences are granted by state drug controllers, while the Central Drugs Standard Control Organisation handles central-level approvals, imports and coordination.

In principle, this is a reasonable division - states are closer to local manufacturing units and can respond faster. In practice, it means no single authority tracks a drug consignment continuously from manufacture through repackaging to hospital delivery.

A batch can cross from an unlicensed unit into a licensed pharmacy's supply chain and the jurisdictional seam between "state matter" and "central matter" is exactly where oversight goes quiet. This isn't a hypothetical vulnerability - it is what the Bidadi case describes in practice.

An unlicensed farmhouse operated with impunity, in coordination with an operating, presumably licensed, Bengaluru pharmacy, for long enough to build relationships with over 90 institutional buyers. That length of operation is the real indictment: it suggests routine surveillance, not just this one raid, is where the system is weakest.

The temptation is to respond with tougher penalties alone. Penalties matter, but they punish after the fact; they do not close the jurisdictional seam that let the network operate undetected in the first place. What would actually close it is a track-and-trace mechanism - mandatory barcoding or serialisation that follows a drug batch from manufacture to dispensation, queryable by both state and central authorities in the same system, so that a batch's provenance can be verified at the point of hospital procurement, not reconstructed after a bust.

There is a real cost to this: track-and-trace infrastructure requires investment that many state drug-testing labs and inspectorates, already short-staffed, would struggle to absorb without central funding and technical support.

But the alternative - leaving the seam between central and state oversight open - has already cost lives, both through this racket's reach into ICU wards and through the cough-syrup deaths abroad that preceded it. India's "pharmacy of the world" ambition depends on foreign regulators trusting Indian-made drugs; that trust erodes faster with each domestic bust than any marketing campaign can rebuild it.

The choice in front of policymakers is not between state autonomy and central control in the abstract - it is between an enforcement architecture built for a world where drugs stayed within one state's borders and one built for a supply chain that now routinely crosses jurisdictional lines faster than either regulator can track it alone.